Want to see CH:CURN full AI Analyst Report?
Curatis Holding AG (CURN) Stock Price & Analysis
CURN Stock Chart & Stats
- Day’s Range
- CHF 17.05 - CHF 17.85
- 52-Week Range
- CHF 11.05 - CHF 27.90
- Previous Close
- CHF 17.40
- Volume
- N/A
- Average Volume (3M)
- 1,876
- Market Cap
- CHF 90.56M
- Enterprise Value
- CHF 111.64M
- Total Cash (Recent Filing)
- CHF 3.60M
- Total Debt (Recent Filing)
- CHF 0
- Price to Earnings (P/E)
- ―
- Beta
- -0.21
- Next Earnings
- Apr 12, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery
The sharp annual revenue recovery indicates improving commercial traction and a stronger demand base than in the prior period. If sustained, higher sales can improve operating leverage, support investment in the pharmaceutical portfolio, and provide a foundation for eventual profitability.
Debt-Free Balance Sheet
Zero reported debt and a substantial equity base give Curatis greater financial flexibility than a leveraged business. This reduces interest burden and refinancing exposure, while preserving capacity to fund development or manage volatility as revenue recovery continues.
Improving Gross Margin
The margin improvement suggests that the recovering revenue base is becoming more economically attractive, not merely larger. Further progress in gross margin could strengthen operating leverage and help narrow losses, provided the improvement persists as commercial activity expands.
Bears Say
Persistent Unprofitability
Curatis has not yet converted its revenue recovery into sustainable earnings, as all key profitability measures remain negative. Continued losses limit internally generated capital, make results more dependent on future improvement, and weaken the durability of the current recovery.
Ongoing Cash Burn
Negative operating and free cash flow show that the business is not yet self-funding, even as reported losses narrow. Persistent cash burn can consume the balance-sheet cushion over time and may constrain Curatis's ability to finance growth without additional funding.
Negative Returns On Equity
A negative return on equity indicates that the sizeable capital base is not currently producing positive economic returns. Unless profitability improves, capital efficiency will remain weak, reducing the strategic benefit of the company's otherwise debt-free financial position.
Curatis Holding AG News
CURN FAQ
What was Curatis Holding AG’s price range in the past 12 months?
What is Curatis Holding AG’s market cap?
When is Curatis Holding AG’s upcoming earnings report date?
How were Curatis Holding AG’s earnings last quarter?
Is Curatis Holding AG overvalued?
Does Curatis Holding AG pay dividends?
What is Curatis Holding AG’s EPS estimate?
How many shares outstanding does Curatis Holding AG have?
What happened to Curatis Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Curatis Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Curatis Holding AG
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Roland Rutschmann
- Employees
- 9
- Website
- curatis.com
- Address
- Weierweg 7, Liestal, BL, 4410, CH
Curatis Holding AG (CURN) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |


